MYP_119703
Basic Information
Novel erythropoiesis stimulating protein (NESP)
Anticancer
Antiviral
Hormonal / Endocrine Hormone peptide
Standard
166 amino acids
C815H1317N233O241S5
Standard
Sequence
APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
Physicochemical Analysis
18395.92 Da
8.75
2.96
2.57
0.0178
-0.19
0.86
-0.02
36.76
96.45
0.0663
22460.00
22710.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
7649.41
-77.10
271.0
251.0
609.0
1294.0
24.0
178.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0337298 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]
9606
Structure & Mods
cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
Three N-linked carbohydrate chains
Bio-Activity Profile
Stimulates erythropoiesis
ELISA
Subcutaneously injected into patients with end-stage renal failure, in vivo; 30600 s
RECORD: Rec_0349484 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]; Cricetulus griseus [Animal]
Erythropoietin analog
9606;10029
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Hematopoietic Erythropoiesis-stimulating
RECORD: Rec_0357700 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]
Growth factor
9606
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Phosphorylation
Bio-Activity Profile
Antiviral Anticancer
**Healthy volunteers:** The half life is approximately 4 hours in healthy volunteers receiving an intravenous injection [F85]. A half-life of approximately 6 hours has been reported in children [F85]., **Adult and paediatric patients with CRF:** The elimination half life following intravenous administration ranges from 4 to 13 hours, which is about 20% longer in CRF patients than that in healthy subjects. The half life is reported to be similar between adult patients receiving or not receiving dialysis [FDA Label]. , **Cancer patients receiving cyclic chemotherapy:** Following subcutaneous administration, the average half life is 40 hours with range of 16 to 67 hours [FDA Label].
Showing 3 records on this page · Page 2 of 2